PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30655615-0	2019	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.	Cyclophosphamide	35-51	BRCA1 DNA repair associated	Homo sapiens	55-59	
22807977-2	2012	Thus, we hypothesized that BRCA1 protein expression and activating PIK3CA mutations are potential tumor biomarkers for the chemotherapeutic response to doxorubicin/cyclophosphamide plus docetaxel in locally advanced breast cancer.	Cyclophosphamide	164-180	BRCA1 DNA repair associated	Homo sapiens	27-32	
27113739-0	2016	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.	Cyclophosphamide	29-45	BRCA1 DNA repair associated	Homo sapiens	108-113	
22357256-3	2012	PATIENTS AND METHODS: DNA was isolated and BRCA1-like status was assessed in 101 patients with early-stage TNBC receiving adjuvant cyclophosphamide-based chemotherapy.	Cyclophosphamide	131-147	BRCA1 DNA repair associated	Homo sapiens	43-48	
22307137-10	2012	CONCLUSIONS: The combination of veliparib with metronomic cyclophosphamide is well tolerated and shows promising activity in a subset of patients with BRCA mutations.	Cyclophosphamide	58-74	BRCA1 DNA repair associated	Homo sapiens	151-155	
25589624-1	2015	PURPOSE: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial.	Cyclophosphamide	94-110	BRCA1 DNA repair associated	Homo sapiens	128-132	
25589624-9	2015	CONCLUSION: This is the first trial that evaluated single-agent, low-dose cyclophosphamide in HGSOC, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers.	Cyclophosphamide	74-90	BRCA1 DNA repair associated	Homo sapiens	133-137	
32097092-0	2020	TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).	Cyclophosphamide	81-97	BRCA1 DNA repair associated	Homo sapiens	110-114	
32175521-11	2020	Conclusions: BRCA1 promoter methylation is predictive of improved disease outcome in patients receiving cyclophosphamide, methotrexate, and fluorouracil drug treatment.	Cyclophosphamide	104-120	BRCA1 DNA repair associated	Homo sapiens	13-18